Publications by authors named "K M Mueller"
Leflunomide can be used in management of psoriatic disease. Leflunomide's active metabolite, teriflunomide, is used in the treatment of multiple sclerosis and has unexpectedly been rarely reported to induce pustular psoriasis. In this report, we present a patient with multiple sclerosis who developed inverse psoriasis after starting teriflunomide.
View Article and Find Full Text PDFArticle Synopsis
- - This study explores the relationship between mild cognitive impairment (MCI), a potential precursor to Alzheimer's disease, and articulatory precision in speech by introducing a new measure called the phoneme log-likelihood ratio (PLLR).
- - Researchers analyzed speech recordings from various groups, including cognitively unimpaired individuals and those with MCI or dementia, and found that MCI and dementia participants displayed reduced speech fluency and pace.
- - The PLLR demonstrated strong effectiveness in distinguishing between cognitively unimpaired participants and those with cognitive decline, highlighting its potential as a sensitive tool for detecting early changes in speech related to cognitive health.
Dear Editor, we read the article "Sarcopenia Prevalence Among Hospitalized Patients with Severe Obesity: An Observational Study" and found it to be of great interest. The exploration of this important topic is highly commendable; however, we would like to highlight a critical issue that has not been fully addressed in this study. Specifically, the study does not fully adhere to the consensus definition of sarcopenic obesity (SO) as outlined by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO), as we will explain below.
View Article and Find Full Text PDFPurpose: Adults with arthritis experience poor health-related quality of life (HRQOL), though research often focuses on single HRQOL outcomes or summary scores. We aimed to identify HRQOL profiles in adults with different arthritis types and determine risk and protective factors.
Methods: Data including PROMIS-29 Profile v2.
Article Synopsis
- The study investigates the safety and efficacy of finerenone in treating heart failure, focusing on differences between men and women.
- Conducted as part of the FINEARTS-HF trial, it included over 6000 participants aged 40 and older across multiple countries.
- Results show that finerenone significantly reduces the risk of combined cardiovascular death and heart failure events in both sexes, with women experiencing slightly better outcomes on average.